CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 68.75% | -2.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 68.75% | -2.81% | |||
| Cost of Revenue | -16.55% | 18.28% | |||
| Gross Profit | 17.09% | -18.45% | |||
| SG&A Expenses | -6.61% | 8.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.37% | 17.06% | |||
| Operating Income | 15.84% | -17.19% | |||
| Income Before Tax | 6.08% | -22.85% | |||
| Income Tax Expenses | 36.64% | -0.81% | |||
| Earnings from Continuing Operations | 5.88% | -22.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.88% | -22.71% | |||
| EBIT | 15.84% | -17.19% | |||
| EBITDA | 15.54% | -16.83% | |||
| EPS Basic | 6.65% | -17.60% | |||
| Normalized Basic EPS | 6.85% | -17.73% | |||
| EPS Diluted | 6.64% | -17.19% | |||
| Normalized Diluted EPS | 6.85% | -17.73% | |||
| Average Basic Shares Outstanding | 0.82% | 4.34% | |||
| Average Diluted Shares Outstanding | 0.82% | 4.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||